查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1766136

全球体外大肠直肠癌筛检市场：2032 年预测 - 按测试类型、影像类型、交付方式、应用、最终用户和地区进行分析

In-vitro Colorectal Cancer Screening Tests Market Forecasts to 2032 - Global Analysis By Test Type, Imaging Type, Mode of Offering, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球体外大肠癌筛检市场预计在 2025 年将达到 12.9 亿美元，预计到 2032 年将达到 21.7 亿美元，预测期内的复合年增长率为 7.7%。

体外大肠直肠癌筛检检测是一种非侵入性诊断方法，可透过分析粪便或血液等体外生物样本来检测大肠直肠癌的早期征兆。这些检测可以识别潜血、DNA突变以及与恶性肿瘤和癌前息肉相关的蛋白质指标等生物标记。常用方法包括大便潜血试验(FOBT)、粪便免疫化学检测 (FIT) 和基于 DNA 的检测。这些检测旨在用于常规筛检，有助于早期发现癌症，改善治疗效果，并在症状出现之前发现癌症，从而降低死亡率。

根据《柳叶刀肿瘤学》的报导，多目标粪便 DNA 测试（例如 Cologuard）在检测结肠直肠癌方面的灵敏度超过 90%，在检测晚期腺瘤方面的灵敏度约为 42%。

大肠直肠癌发生率和盛行率上升

对于寻求改善患者治疗效果并降低治疗成本的医疗保健提供者而言，早期检测正成为首要任务。随着公共卫生计画持续强调对45岁及以上人口进行定期筛检，预计检测量将大幅成长。此外，癌症协会和政府机构的宣传活动也推动了对非侵入性检测的需求。人们日益认识到筛检是一种预防策略，而非被动应对，这进一步佐证了这一趋势。

常规检测的敏感性和特异性降低

传统的筛检方法，例如癒创木脂检测和过时的粪便检测，通常敏感性和特异性有限，导致假阳性和漏诊。这些缺陷降低了临床医生和患者对检测的信心，并阻碍了采用大肠镜检查等更明确的诊断方法。此外，由于生物标记可见度较差，检测延迟的风险可能导致无症状患者的病情进展。

向服务不足和资源匮乏的环境扩张

农村和资源匮乏的地区通常缺乏先进的诊断基础设施，这构成了一个尚未开发的庞大市场。携带式、无需专业知识的自助式试剂套件可以填补这一空白，尤其是透过政府支持的社区健康计画进行分发。随着官民合作关係的扩展，相关人员越来越注重透过根据不同的社会经济背景客製化筛检解决方案来改善医疗保健公平性。

对结果的误解和过度诊断/诊断不足

不准确的结果可能导致过度诊断，使患者面临侵入性干预，或诊断不足，从而延误治疗并降低疗效。不同族群检测结果的差异增加了临床的复杂性，需要谨慎应用并由专家监督。此外，医疗系统中指南的不标准化也导致结果解释和追踪通讯协定的混乱。这些因素引发了人们对责任问题的担忧，并凸显了对临床医生进行培训和製定更完善的检验通讯协定的必要性。

COVID-19的影响：

COVID-19 疫情扰乱了全球癌症筛检服务，并延迟了大肠直肠疾病的早期诊断。封锁和医院就诊限制减少了常规筛检，导致大量未确诊病例积压。另一方面，疫情凸显了居家和远距离诊断的价值，促使人们对自助采集套件以及与远端医疗结合的检测方法重新燃起兴趣。此类行为变化可能会对筛检策略产生持久影响，并可能加速体外诊断解决方案的发展。

预计大便潜血试验（FOBT）部分在预测期内将占据最大的份额。

大便潜血试验(FOBT) 因其成本效益高、普及性强且非侵入性，预计将在预测期内占据最大的市场占有率。 FOBT 在许多国家癌症预防计画中被用作第一线筛检工具，易于分发和管理。其便利性和极低的基础设施要求使其成为在已开发市场和新兴市场大规模部署的理想选择。

MarCarePlex 部门预计在预测期内实现最高复合年增长率

在预测期内，MarCarePlex 细分市场预计将呈现最高成长率，这得益于其多重生物标记方法和高诊断准确性。这些先进的检测方法能够同时检测多种癌症特异性标记物，从而提供更全面的风险评估。它们能够有效识别早期恶性肿瘤，因此对于寻求精准且可扩展的检测解决方案的临床实验室而言极具吸引力。

比最大的地区

由于完善的筛检指南和广泛的医疗保险计划，北美预计将在预测期内占据最大的市场占有率。美国疾病管制与预防中心 (CDC) 和美国癌症协会 (ACS) 等机构进行的广泛宣传宣传活动和积极的筛检计画正在提高各年龄层的参与率。雄厚的癌症预防研究资金和早期技术应用进一步提升了该地区的市场前景。

复合年增长率最高的地区：

在预测期内，由于公共卫生计画的不断增加以及对预防性诊断的日益重视，预计欧洲地区将呈现最高的复合年增长率。德国、英国和法国等国家正在扩大其国家癌症筛检计划，将高风险族群纳入其中。技术创新，尤其是生物标记发现和人工智慧主导的分析，正在该地区的医疗科技生态系统中日益受到关注。

免费客製化服务

本报告的所有订阅者均可享有以下免费自订选项之一：

  • 公司简介
    • 对其他公司（最多 3 家）进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 简介

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 主要研究资料
    • 二手研究资讯来源
    • 先决条件

第三章市场走势分析

  • 介绍
  • 驱动程式
  • 限制因素
  • 市场机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代产品的威胁
  • 新参与企业的威胁
  • 企业之间的竞争

5. 全球体外大肠直肠癌筛检测试市场（依测试类型）

  • 大便潜血试验（FOBT）
    • 癒创木脂粪便潜血试验（gFOBT）
    • 粪便免疫化学检查（FIT 或 iFOBT）
  • 粪便DNA检测（sDNA）
    • 多目标粪便DNA检测
    • 甲基化基因检测
    • 面板 DNA 检测
  • 生物标记检测（血液检测）
    • 肿瘤M2-PK粪便检验
    • 转铁蛋白测定
    • 血浆甲基化 SEPT9 DNA 检测
    • 液态生物检体
  • 其他类型的测试

6. 全球体外大肠直肠癌筛检检测市场（依影像类型）

  • 大肠镜检查
  • 直肠镜检查
  • 电脑断层扫描
  • 超音波
  • PET扫描
  • MRI

7. 全球体外大肠直肠癌筛检测试市场（以交付方式）

  • 医师主导的筛检
  • 直接面向消费者（DTC）的家用检测

8. 全球体外大肠直肠癌筛检测试市场（依应用）

  • MarCarePlex
  • Cologic
  • Colox
  • miRDIGN
  • PanCDx
  • MeSorce CRC

9. 全球体外大肠直肠癌筛检测试市场（依最终用户划分）

  • 医院
  • 诊所
  • 诊断实验室
  • 门诊手术中心
  • 其他最终用户

第十章 全球体外大肠直肠癌筛检测试市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併与收购（M&A）
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Sysmex Corporation
  • Siemens Healthcare GmbH
  • Randox Laboratories Ltd.
  • Quest Diagnostics Incorporated
  • OncoCyte Corporation
  • Merck KGaA
  • Kyowa Kirin Co., Ltd.
  • Invitae Corporation
  • Immunostics Inc.
  • Illumina, Inc.
  • Hologic, Inc.
  • Genomic Health, Inc.
  • F. Hoffmann-La Roche AG
  • Exact Sciences Corporation
  • Epigenomics AG
  • Eiken Chemical Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Beckman Coulter Inc.
  • Abbott Laboratories
Product Code: SMRC29992

According to Stratistics MRC, the Global In-vitro Colorectal Cancer Screening Tests Market is accounted for $1.29 billion in 2025 and is expected to reach $2.17 billion by 2032 growing at a CAGR of 7.7% during the forecast period. In-vitro colorectal cancer screening tests are non-invasive diagnostic procedures that analyze biological samples typically stool or blood outside the body to detect early signs of colorectal cancer. These tests identify biomarkers such as occult blood, DNA mutations, or protein indicators associated with malignancies or precancerous polyps. Common methods include fecal occult blood tests (FOBT), fecal immunochemical tests (FIT), and DNA-based assays. Designed for routine screening, they support early detection, improve treatment outcomes, and reduce mortality by identifying cancer before symptoms appear

According to article in The Lancet Oncology, multitarget stool DNA tests (such as Cologuard) showed a sensitivity of over 90% for detecting colorectal cancer and around 42% for advanced adenomas.

Market Dynamics:

Driver:

Rising incidence and prevalence of colorectal cancer

Early detection is becoming a top priority for healthcare providers aiming to improve patient outcomes and reduce treatment costs. As public health programs continue emphasizing routine screening for individuals aged 45 and above, test volumes are expected to rise substantially. Moreover, awareness initiatives by cancer associations and governmental bodies are bolstering demand for non-invasive testing. This trend is further supported by the growing recognition of screening as a preventive strategy rather than a reactive measure.

Restraint:

Lower sensitivity and specificity of traditional tests

Conventional screening options, such as guaiac-based tests or outdated fecal assays, often suffer from limited sensitivity and specificity, resulting in false positives or missed diagnoses. These shortcomings can erode clinician and patient confidence in the tests, discouraging adoption in favor of more definitive diagnostics like colonoscopy. Additionally, the risk of under-detection due to low biomarker visibility may lead to disease progression in asymptomatic patients.

Opportunity:

Expansion into underserved and low-resource settings

Populations in rural or low-resource settings often lack access to advanced diagnostic infrastructure, creating a large untapped market. Portable, self-administered kits that require minimal expertise can bridge this gap, especially when distributed through government-backed community health programs. As public-private partnerships expand, stakeholders are increasingly focused on improving healthcare equity by tailoring screening solutions to diverse socioeconomic contexts.

Threat:

Misinterpretation of results and over-diagnosis/under-diagnosis

Inaccurate results may lead to over-diagnosis, subjecting patients to invasive interventions, or under-diagnosis, delaying treatment and worsening prognosis. Variability in test performance across populations adds to clinical complexity, requiring cautious application and expert oversight. Additionally, non-standardized guidelines across healthcare systems contribute to confusion in result interpretation and follow-up protocols. These factors heighten liability concerns and emphasize the need for clinician training and better validation protocols.

Covid-19 Impact:

The COVID-19 pandemic introduced disruptions to cancer screening services worldwide, delaying early diagnosis of colorectal conditions. Lockdowns and restricted hospital access led to a decline in routine check-ups, causing a backlog of undiagnosed cases. On the other hand, the pandemic highlighted the value of home-based and remote diagnostics, prompting renewed interest in self-collection kits and telehealth-integrated testing. This shift in behavior is likely to have lasting effects on screening strategies and could serve as a growth accelerator for in-vitro solutions.

The fecal occult blood test (FOBT) segment is expected to be the largest during the forecast period

The fecal occult blood test (FOBT) segment is expected to account for the largest market share during the forecast period due to its cost-effectiveness, wide availability, and non-invasive nature. Used as a frontline screening tool in numerous national cancer prevention programs, FOBTs are easily distributed and administered. Their convenience and minimal infrastructure requirements make them ideal for large-scale deployments across both developed and emerging markets.

The marcareplex segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the marcareplex segment is predicted to witness the highest growth rate driven by its multiplex biomarker approach and high diagnostic precision. These advanced assays can detect multiple cancer-specific markers simultaneously, providing a more comprehensive risk assessment. Their efficiency in identifying early-stage malignancies makes them attractive for clinical labs seeking accurate yet scalable testing solutions.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share attributed to well-established screening guidelines and expansive health coverage systems. Widespread awareness campaigns and proactive screening initiatives by agencies like the CDC and ACS have boosted participation rates across demographics. Strong funding for cancer prevention research and early technology adoption further enhance the regional market outlook.

Region with highest CAGR:

Over the forecast period, the Europe region is anticipated to exhibit the highest CAGR owing to increased public health initiatives and growing emphasis on preventive diagnostics. Countries such as Germany, the U.K., and France are expanding national cancer screening programs to include high-risk populations. Technological innovation, particularly in biomarker discovery and AI-driven analytics, is gaining traction in the region's med-tech ecosystem.

Key players in the market

Some of the key players in In-vitro Colorectal Cancer Screening Tests Market include Sysmex Corporation, Siemens Healthcare GmbH, Randox Laboratories Ltd., Quest Diagnostics Incorporated, OncoCyte Corporation, Merck KGaA, Kyowa Kirin Co., Ltd., Invitae Corporation, Immunostics Inc., Illumina, Inc., Hologic, Inc., Genomic Health, Inc., F. Hoffmann-La Roche AG, Exact Sciences Corporation, Epigenomics AG, Eiken Chemical Co., Ltd., Bio-Rad Laboratories, Inc., Beckman Coulter Inc. and Abbott Laboratories.

Key Developments:

In June 2025, Illumina agreed to buy proteomics company SomaLogic for $350 million plus milestones, bolstering its multiomics capabilities. The deal enhances its strategy across genomics, proteomics, and personalized medicine

In May 2025, Siemens Healthineers launched the first U.S. Mobile Stroke Unit equipped with a Somatom On.site CT scanner to deliver advanced stroke diagnostics at UCLA Health. This rapid-response ambulance aims to reduce treatment delays and improve outcomes.

Test Types Covered:

  • Fecal Occult Blood Test (FOBT)
  • Stool DNA Test (sDNA)
  • Biomarker Tests (Blood-based Tests)
  • Other Test Types

Imaging Types Covered:

  • Colonoscopy
  • Proctoscopy
  • CT Scan
  • Ultrasound
  • PET Scan
  • MRI

Mode of Offerings Covered:

  • Physician-Led Screening
  • Direct-to-Consumer (DTC) Home Testing

Applications Covered:

  • MarCarePlex
  • Cologic
  • Colox
  • miRDIGN
  • PanCDx
  • MeSorce CRC

End Users Covered:

  • Hospitals
  • Clinics
  • Diagnostic Laboratories
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global In-vitro Colorectal Cancer Screening Tests Market, By Test Type

  • 5.1 Introduction
  • 5.2 Fecal Occult Blood Test (FOBT)
    • 5.2.1 Guaiac FOBT (gFOBT)
    • 5.2.2 Fecal Immunochemical Test (FIT or iFOBT)
  • 5.3 Stool DNA Test (sDNA)
    • 5.3.1 Multitarget Stool DNA Testing
    • 5.3.2 Methylated Gene Testing
    • 5.3.3 Panel DNA Tests
  • 5.4 Biomarker Tests (Blood-based Tests)
    • 5.4.1 Tumor M2-PK Stool Test
    • 5.4.2 Transferrin Assays
    • 5.4.3 Plasma Methylated SEPT9 DNA Assay
    • 5.4.4 Liquid Biopsy
  • 5.5 Other Test Types

6 Global In-vitro Colorectal Cancer Screening Tests Market, By Imaging Type

  • 6.1 Introduction
  • 6.2 Colonoscopy
  • 6.3 Proctoscopy
  • 6.4 CT Scan
  • 6.5 Ultrasound
  • 6.6 PET Scan
  • 6.7 MRI

7 Global In-vitro Colorectal Cancer Screening Tests Market, By Mode of Offering

  • 7.1 Introduction
  • 7.2 Physician-Led Screening
  • 7.3 Direct-to-Consumer (DTC) Home Testing

8 Global In-vitro Colorectal Cancer Screening Tests Market, By Application

  • 8.1 Introduction
  • 8.2 MarCarePlex
  • 8.3 Cologic
  • 8.4 Colox
  • 8.5 miRDIGN
  • 8.6 PanCDx
  • 8.7 MeSorce CRC

9 Global In-vitro Colorectal Cancer Screening Tests Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 Diagnostic Laboratories
  • 9.5 Ambulatory Surgical Centers
  • 9.6 Other End Users

10 Global In-vitro Colorectal Cancer Screening Tests Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Sysmex Corporation
  • 12.2 Siemens Healthcare GmbH
  • 12.3 Randox Laboratories Ltd.
  • 12.4 Quest Diagnostics Incorporated
  • 12.5 OncoCyte Corporation
  • 12.6 Merck KGaA
  • 12.7 Kyowa Kirin Co., Ltd.
  • 12.8 Invitae Corporation
  • 12.9 Immunostics Inc.
  • 12.10 Illumina, Inc.
  • 12.11 Hologic, Inc.
  • 12.12 Genomic Health, Inc.
  • 12.13 F. Hoffmann-La Roche AG
  • 12.14 Exact Sciences Corporation
  • 12.15 Epigenomics AG
  • 12.16 Eiken Chemical Co., Ltd.
  • 12.17 Bio-Rad Laboratories, Inc.
  • 12.18 Beckman Coulter Inc.
  • 12.19 Abbott Laboratories

List of Tables

  • Table 1 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 3 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Fecal Occult Blood Test (FOBT) (2024-2032) ($MN)
  • Table 4 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Guaiac FOBT (gFOBT) (2024-2032) ($MN)
  • Table 5 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Fecal Immunochemical Test (FIT or iFOBT) (2024-2032) ($MN)
  • Table 6 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Stool DNA Test (sDNA) (2024-2032) ($MN)
  • Table 7 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Multitarget Stool DNA Testing (2024-2032) ($MN)
  • Table 8 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Methylated Gene Testing (2024-2032) ($MN)
  • Table 9 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Panel DNA Tests (2024-2032) ($MN)
  • Table 10 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Biomarker Tests (Blood-based Tests) (2024-2032) ($MN)
  • Table 11 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Tumor M2-PK Stool Test (2024-2032) ($MN)
  • Table 12 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Transferrin Assays (2024-2032) ($MN)
  • Table 13 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Plasma Methylated SEPT9 DNA Assay (2024-2032) ($MN)
  • Table 14 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Liquid Biopsy (2024-2032) ($MN)
  • Table 15 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Other Test Types (2024-2032) ($MN)
  • Table 16 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Imaging Type (2024-2032) ($MN)
  • Table 17 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Colonoscopy (2024-2032) ($MN)
  • Table 18 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Proctoscopy (2024-2032) ($MN)
  • Table 19 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By CT Scan (2024-2032) ($MN)
  • Table 20 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Ultrasound (2024-2032) ($MN)
  • Table 21 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By PET Scan (2024-2032) ($MN)
  • Table 22 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By MRI (2024-2032) ($MN)
  • Table 23 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Mode of Offering (2024-2032) ($MN)
  • Table 24 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Physician-Led Screening (2024-2032) ($MN)
  • Table 25 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Direct-to-Consumer (DTC) Home Testing (2024-2032) ($MN)
  • Table 26 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Application (2024-2032) ($MN)
  • Table 27 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By MarCarePlex (2024-2032) ($MN)
  • Table 28 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Cologic (2024-2032) ($MN)
  • Table 29 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Colox (2024-2032) ($MN)
  • Table 30 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By miRDIGN (2024-2032) ($MN)
  • Table 31 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By PanCDx (2024-2032) ($MN)
  • Table 32 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By MeSorce CRC (2024-2032) ($MN)
  • Table 33 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By End User (2024-2032) ($MN)
  • Table 34 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 35 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 36 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 37 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 38 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.